ondansetron has been researched along with Thromboembolism, Venous in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Datta, A | 1 |
| Matlock, MK | 1 |
| Le Dang, N | 1 |
| Moulin, T | 1 |
| Woeltje, KF | 1 |
| Yanik, EL | 1 |
| Joshua Swamidass, S | 1 |
1 other study available for ondansetron and Thromboembolism, Venous
| Article | Year |
|---|---|
'Black Box' to 'Conversational' Machine Learning: Ondansetron Reduces Risk of Hospital-Acquired Venous Thromboembolism.
Topics: Hospitals; Humans; Machine Learning; Ondansetron; Retrospective Studies; Risk Factors; Venous Thromb | 2021 |